Imugene Limited
(ASX:IMU) says its leading cancer vaccination is showing a dramatic ten-fold increase in antibodies and has met an additional milestone.
The treatment is aimed towards various tumours including stomach, breast, ovarian and lung cancers.
The HER-Vaxx immunotherapy has just been reformulated and is showing a much faster and stronger immune response as well as indicating that a potentially lower dose and fewer immunisations could be required.
Imugene has filed a new patent for the product, extending coverage to 2036.
Imugene reported a net loss of $1.05 million for the first six months of the 2015 financial year.
